Panacea share spurt on govt vaccine order and prequalification prospects
This article was originally published in Scrip
Shares of India's second-largest vaccines producer, Panacea Biotec, rose on Indian bourses after the company bagged a government order worth more than Rs1.87 billion ($34.4 million) for the supply of 345 million doses of oral polio vaccine.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.